Localization of Pancreatic Cancer With Radiolabeled Monoclonal Antibody PAM4

Crit Rev Oncol Hematol. Jul-Aug 2001;39(1-2):147-54. doi: 10.1016/s1040-8428(01)00114-7.


Experimental animal studies were performed with (111)In-labeled PAM4 anti-MUC1 antibody along with (111)In-labeled control antibody. Tumor uptake of radiolabeled PAM4 was significantly higher than for the control antibody at all time points. When normalized to a blood dose of 1500 cGy as an estimate of myelotoxicity, (90)Y-labeled PAM4 would provide 5344 cGy to the tumor, whereas an equitoxic dose of (90)Y-labeled control antibody would provide only 862 cGy to the tumor. In addition to the animal studies, five patients with proven pancreatic cancer were administered either (131)I-PAM4 IgG (n=2) or 99mTc-PAM4 Fab' (n=3). Tumor targeting was observed in four out of five patients. By immunohistochemistry, PAM4 was non-reactive with tumor from the one patient not targeted. Dosimetry from the patients given (131)I-PAM4 predicted that tumors would receive 10-20 cGy/mCi with tumor/red marrow dose ratios ranging from 3 to 10. Based upon these results, we have established a phase-I (111)In-labeled PAM4 imaging and (90)Y-labeled PAM4 therapy trial.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Neoplasm / therapeutic use*
  • Antigens, Tumor-Associated, Carbohydrate / immunology
  • Female
  • Humans
  • Male
  • Mice
  • Mice, Nude
  • Middle Aged
  • Mucin-1 / immunology
  • Neoplasm Transplantation
  • Pancreatic Neoplasms / diagnostic imaging*
  • Pancreatic Neoplasms / radiotherapy*
  • Pharmacokinetics
  • Radioimmunodetection / methods
  • Radioimmunotherapy / methods
  • Tomography, Emission-Computed


  • Antibodies, Monoclonal
  • Antibodies, Neoplasm
  • Antigens, Tumor-Associated, Carbohydrate
  • Mucin-1